Sustainable Responses in Metastatic Melanoma Patients After Elective Discontinuation of Anti–PD1-Based Immunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Sustainable Responses in Metastatic Melanoma Patients With and Without Brain Metastases After Elective Discontinuation of Anti-PD1-Based Immunotherapy Due to Complete Response
Eur. J. Cancer 2021 May 01;[EPub Ahead of Print], F Dimitriou, A Zaremba, C Allayous, KC Kähler, CL Gerard, L Festino, S Schäfer, F Toussaint, L Heinzerling, JC Hassel, PA Ascierto, O Michielin, A Hauschild, C Lebbe, E Livingstone, E Ramelyte, PF Cheng, R Dummer, J ManganaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.